Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma

Blog Article

Lenvatinib, an oral small-molecule multiple tyrosine kinase here inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC).Proteinuria is one of the most common adverse events associated with lenvatinib treatment.We reported a 67-year-old Thai female was diagnosed with NASH cirrhosis and HCC BCLC B with TACE refractoriness.

She received 8 mg of lenvatinib for 2 weeks and began to experience worsening hypertension, bilateral pleural effusion, pedal edema, hypoalbuminemia, hypercholesterolemia, and proteinuria.After exclusion of all possible causes, lenvatinib-induced nephrotic syndrome (NS) was diagnosed.One week after discontinuing the drug, her symptoms gradually improved.

To date, there have been only a handful of reported cases of lenvatinib-induced nephrotoxicity.We report herein the case of lenvatinib-induced NS in a cirrhotic patient with HCC 5326058hx with resolution of symptoms in a short period after drug discontinuation.In addition, we reviewed all reported cases of lenvatinib-induced nephrotoxicity.